Xiaolei F. Wei

No. 1838 North Guangzhou Avenue
Guangzhou, 510515, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.

A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: April 24, 2026

XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells.

XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells.

Journal: Hematology (Amsterdam, Netherlands)

Published: February 03, 2026

Multiple Sclerosis and Hematologic Malignancies: A Bidirectional Mendelian Randomization Study.

Multiple Sclerosis and Hematologic Malignancies: A Bidirectional Mendelian Randomization Study.

Journal: Journal of visualized experiments : JoVE

Published: February 02, 2026

Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL).

Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL).

Journal: Cancer biology & therapy

Published: November 12, 2025

FOXO3 upregulates and activates GSDME to trigger myeloma cell pyroptosis.

FOXO3 upregulates and activates GSDME to trigger myeloma cell pyroptosis.

Journal: International journal of biological sciences

Published: September 06, 2025

The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.

The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study.

Journal: BMC cancer

Published: July 01, 2025

PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance.

PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance.

Journal: Science immunology

Published: June 13, 2025

Addition of anti-CD38 mAb in newly diagnosed multiple myeloma: advancing toward quadruplet induction regimens.

Addition of anti-CD38 mAb in newly diagnosed multiple myeloma: advancing toward quadruplet induction regimens.

Journal: Blood neoplasia

Published: June 06, 2025

Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma.

Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma.

Journal: Immunobiology

Published: March 20, 2025

Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.

Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial.

Journal: Journal of translational medicine

Published: March 09, 2025

Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study.

Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study.

Journal: Discover oncology

Published: February 13, 2025

A novel prognostic model utilizing TMTV and SUVmax from 18F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma.

A novel prognostic model utilizing TMTV and SUVmax from 18F-FDG PET/CT for predicting overall survival in patients with extranodal NK/T- cell lymphoma.

Journal: BMC cancer

Published: November 13, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026